Division of Vascular Surgery and Endovascular Therapy, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
JACC Cardiovasc Interv. 2021 Mar 22;14(6):678-688. doi: 10.1016/j.jcin.2021.01.004.
The aim of this study was to describe physician practice patterns and examine physician-level factors associated with the use of atherectomy during index revascularization for patients with femoropopliteal peripheral artery disease.
There are minimal data to support the routine use of atherectomy over angioplasty and/or stenting for the endovascular treatment of peripheral artery disease.
Medicare fee-for-service claims (January 1 to December 31, 2019) were used to identify all beneficiaries undergoing elective first-time femoropopliteal peripheral vascular intervention (PVI) for claudication or chronic limb-threatening ischemia. Hierarchical logistic regression was used to evaluate patient- and physician-level characteristics associated with atherectomy.
A total of 58,552 patients underwent index femoropopliteal PVI by 1,627 physicians. There was a wide distribution of physician practice patterns in the use of atherectomy, ranging from 0% to 100% (median 55.1%). Independent characteristics associated with atherectomy included treatment for claudication (vs. chronic limb-threatening ischemia; odds ratio [OR]: 1.51), patient diabetes (OR: 1.09), physician male sex (OR: 2.08), less time in practice (OR: 1.41 to 2.72), nonvascular surgery specialties (OR: 2.78 to 5.71), physicians with high volumes of femoropopliteal PVI (OR: 1.67 to 3.51), and physicians working primarily at ambulatory surgery centers or office-based laboratories (OR: 2.19 to 7.97) (p ≤ 0.03 for all). Overall, $266.8 million was reimbursed by Medicare for index femoropopliteal PVI in 2019. Of this, $240.6 million (90.2%) was reimbursed for atherectomy, which constituted 53.8% of cases.
There is a wide distribution of physician practice patterns for the use of atherectomy during index PVI. There is a critical need for professional guidelines outlining the appropriate use of atherectomy in order to prevent overutilization of this technology, particularly in high-reimbursement settings.
本研究旨在描述医生的实践模式,并探讨与股腘外周动脉疾病血管腔内再通治疗中使用旋切术相关的医生层面因素。
在血管腔内治疗外周动脉疾病方面,旋切术相对于单纯球囊扩张术和/或支架置入术的常规应用,仅有很少的数据支持。
利用 2019 年 1 月 1 日至 12 月 31 日期间的 Medicare 按服务项目付费(fee-for-service)索赔数据,确定所有接受择期首次股腘外周血管腔内干预(PVI)治疗间歇性跛行或慢性肢体威胁性缺血的受益人的信息。采用分层逻辑回归分析评估与旋切术应用相关的患者和医生特征。
共有 58552 名患者接受了 1627 名医生施行的股腘 PVI 指数治疗。在旋切术的应用中,医生的实践模式分布广泛,从 0%到 100%(中位数为 55.1%)。与旋切术应用相关的独立特征包括治疗间歇性跛行(与慢性肢体威胁性缺血相比;比值比[OR]:1.51)、患者糖尿病(OR:1.09)、医生为男性(OR:2.08)、从业时间较短(OR:1.41 至 2.72)、非血管外科专业(OR:2.78 至 5.71)、股腘 PVI 高工作量的医生(OR:1.67 至 3.51)以及主要在门诊手术中心或基于办公室的实验室工作的医生(OR:2.19 至 7.97)(所有 p 值均≤0.03)。总体而言,2019 年 Medicare 为股腘 PVI 指数治疗支付了 2.668 亿美元的报销费用。其中,2.406 亿美元(90.2%)用于旋切术报销,占病例的 53.8%。
在股腘 PVI 指数治疗中,医生使用旋切术的实践模式分布广泛。为了防止这种技术的过度应用,特别是在高报销环境中,迫切需要制定专业指南,概述旋切术的合理应用。